Novel NGF signaling identified as a driver of lenvatinib resistance in hepatocellular carcinoma, suggesting TrkA inhibition as a potential treatment strategy.
This study identifies a novel NGF associated signaling axis as a key driver of lenvatinib resistance in HCC. These findings offer new insights into NGF-mediated TKI resistance in non-neural tumors and suggest TrkA inhibition as a promising therapeutic strategy for overcoming lenvatinib resistance in clinical practice.
No takes yet. Share an insight, caveat, or question.
陈俊博(chen junbo) (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: